REG - Celadon Pharma. PLC - Notice of AGM

Celadon PharmaceuticalsAnnouncement

31/05/2022 13:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220531:nRSe4321Na&default-theme=true

RNS Number : 4321N  Celadon Pharmaceuticals PLC  31 May 2022

 

Celadon Pharmaceuticals Plc

 

("Celadon" or the "Company")

 

Publication of Annual Report and Notice of Annual General Meeting

 

Celadon Pharmaceuticals Plc, a leading UK based pharmaceutical company focused
on the development and supply of natural cannabis-based medicines, announces
that copies of the 2021 Annual Report and Accounts, together with its Notice
of 2022 Annual General Meeting ("AGM"), were posted to shareholders today and
are available for viewing on the Company's website www.celadonpharma.com
(http://www.celadonpharma.com) .

 

The Company will be holding its AGM at 4.00pm on Monday 27 June 2022 at the
Edgbaston Park Hotel and Conference Centre, 53 Edgbaston Park Road,
Birmingham, B15 2RS.

 

Enquiries:

 Celadon Pharmaceuticals Plc
 James Short                                               Via Powerscourt

 Arthur Wakeley

 Canaccord Genuity Limited (Nominated Adviser and Broker)
 Andrew Potts / Patrick Dolaghan                           +44 (0)20 7523 8000

 Powerscourt Group
 Sarah MacLeod / Nick Johnson / Sam Austrums /             +44 (0)20 7250 1446

 Ibrahim Khalil                                            celadon@powerscourt-group.com

 

About Celadon Pharmaceuticals Plc

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on
the research, cultivation, manufacturing, and supply of natural cannabis-based
medicines. Its primary focus is on improving quality of life for chronic pain
sufferers, as well as exploring the potential of cannabis-based medicines for
other conditions such as autism. Its 100,000 sq. ft UK facility comprises a
laboratory designed to meet GMP standards, and capacity for a large indoor
hydroponic growing facility that has received a Home Office License to legally
grow high-THC medicinal cannabis for the purpose of producing test batches of
cannabis oil to support its application to the MHRA. The Company's subsidiary,
LVL, owns a MHRA conditionally-approved cannabis trial using cannabis based
medicinal products to treat chronic pain in the UK.

 

For further information please visit our website www.celadonpharma.com
(http://www.celadonpharma.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOABKDBNBBKDKPN